RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $80 to $70.
November 10, 2023 | 7:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intellia Therapeutics' Outperform rating is maintained by RBC Capital, though the price target has been lowered from $80 to $70.
While the Outperform rating suggests continued confidence in Intellia Therapeutics' potential, the reduction in price target may reflect a reassessment of near-term growth expectations or market conditions. This could lead to mixed reactions in the short term, as investors weigh the positive rating against the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100